CLAIMS

1. A ~~method for treating pancreatic cancer comprising administering to a subject in need thereof a therapeutically effective amount of a~~ toll-like receptor 9 (TLR9) agonist having the structure: 5'-TCG AAC GTT CGA ACG TTC GAA CGT TCG AAT-3' (SEQ ID NO: 1) for use in the treatment of pancreatic cancer.

2. The use of claim 1, wherein the TLR9 agonist is to be administered through a device by pancreatic retrograde venous infusion (PRVI).

3. The use ~~method~~ of claim 1, wherein the TLR9 agonist is to be administered in an amount ~~is~~ selected from the group consisting of 0.5 mg, 2 mg, 4 mg, 8 mg, or 12 mg.

4. The use ~~method~~ of claim 2, wherein the TLR9 agonist ~~may~~ is to be administered through a catheter device.

5. The use ~~method~~ of claim 4, wherein the catheter device is a temporary occlusion device.

6. The use ~~method~~ of claim ~~4~~2, wherein the TLR9 agonist is to be administered through the catheter device via pressure-enabled drug delivery.

7. The use ~~method~~ of claim ~~6~~7, wherein the TLR9 agonist is to be administered at ~~with~~ a rate of infusion of about 1 mL per minute to about 10 ml per minute~~.~~.

8. The use ~~method~~ of claim 7, wherein the TLR9 agonist is to be administered for a period of time of two to twenty minutes.

9. The use ~~method~~ of claim 1, wherein the TLR9 agonist is to be administered in combination with one or more checkpoint inhibitors, wherein the checkpoint inhibitors are to be administered systemically, either concurrently, before, or after ~~the administration of~~ the TLR9 agonist is to be administered.

10. The use ~~method~~ of claim 9~~10~~, wherein the one or more checkpoint inhibitors include at least one of nivolumab, pembrolizumab, and cemiplimab, atezolizumab, avelumab, and durvalumab, and ipilimumab.

11. The use ~~method~~ of claim 1, wherein ~~the administration of~~ the TLR9 agonist is to be administered according to ~~comprises~~ a dosing regimen comprising cycles, in which one or more of the cycles comprise wherein ~~the administration of~~ the TLR9 agonist is to be administered via a catheter device by pancreatic retrograde venous infusion (PRVI) followed by ~~the systemic administration of~~ a checkpoint inhibitor to be administered systemically.

12. The use ~~method~~ of claim ~~10~~11, wherein the one or more checkpoint inhibitors include at least one of nivolumab, pembrolizumab, and cemiplimab, atezolizumab, avelumab, and durvalumab, and ipilimumab.